Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 20/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 3/20 | 1.00 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Netarsudil-M1 SCHEMBL30607237 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil-M1 SCHEMBL30692376 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil-M1 SCHEMBL21412824 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil-M1 SCHEMBL21430354 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil-M1 SCHEMBL30607241 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil-M1 SCHEMBL30607238 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil-M1 SCHEMBL111706 | 0.99 | ROCK2 (0.98) | ROCK2ROCK1MYLK4 | |
| SCHEMBL20016619 | 0.90 | ROCK2 (0.82) | ROCK2ROCK1MYLK4 | |
| SCHEMBL23927626 | 0.89 | ROCK2 (0.80) | ROCK2ROCK1MYLK4 | |
| SCHEMBL13074858 | 0.89 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144778-A1 | MONO-(ACID) SALTS OF 6-AMINOISOQUINOLINES AND USES THEREOF | ALCON INC. (CH) | 2022-05-12 | — | — | US | claimed |
| CN-111936139-A | Mono (acid) salts of 6-aminoisoquinoline and uses thereof | 爱瑞制药公司 | 2020-11-13 | — | — | CN | claimed |
| US-20190322625-A1 | MONO-(ACID) SALTS OF 6-AMINOISOQUINOLINES AND USES THEREOF | ALCON INC. (CH) | 2019-10-24 | — | — | US | claimed |
| US-20260034056-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING OCULAR DISEASES OR DISORDERS | ALCON INC (CH) | 2026-02-05 | — | — | US | disclosed |
| US-12478577-B2 | Pharmaceutical compositions for treating ocular diseases or disorders | ALCON INC. (CH) | 2025-11-25 | — | — | US | disclosed |
| CN-118304422-A | Pharmaceutical composition for treating eye diseases or disorders | 爱瑞制药公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-118286445-A | Pharmaceutical composition for treating eye diseases or disorders | 爱瑞制药公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-113784727-B | Pharmaceutical composition for treating eye diseases or disorders | 爱瑞制药公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20240065970-A1 | MEDICAL IMPLANT | ALCON INC. (CH) | 2024-02-29 | — | — | US | disclosed |
| CN-117050013-A | Mono (acid) salts of 6-aminoisoquinolines and use thereof | 爱瑞制药公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-111936139-B | Mono (acid) salts of 6-aminoisoquinolines and use thereof | 爱瑞制药公司 | 2023-10-13 | — | — | CN | disclosed |
| US-20150175549-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | AERIE PHARMACEUTICALS, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20140187617-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | AERIE PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-8716310-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130158015-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | AERIE PHARMACEUTICALS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-8394826-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394826-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120135984-A1 | DUAL-ACTION INHBITORS AND METHODS OF USING SAME | AERIE PHARMACEUTICALS, INC. | 2012-05-31 | — | — | US | disclosed |
| US-20100280011-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2010-11-04 | — | — | US | disclosed |
| US-20100280011-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187617-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | ROCK2 3/4885ROCK1 10/4885MYLK4 146/4885 |
| US-20190322625-A1 | MONO-(ACID) SALTS OF 6-AMINOISOQUINOLINES AND USES THEREOF | AADAT, SLC10A1, SLC10A2 | ROCK2 3307/4885ROCK1 3706/4885MYLK4 2031/4885 |
| US-20130158015-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | ROCK2 3/4885ROCK1 10/4885MYLK4 146/4885 |
| US-20260034056-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING OCULAR DISEASES OR DISORDERS | KDR, FLT4, FLT1 | ROCK2 52/4885ROCK1 46/4885MYLK4 469/4885 |
| US-20150175549-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | ROCK2 3/4885ROCK1 10/4885MYLK4 146/4885 |
| US-20220144778-A1 | MONO-(ACID) SALTS OF 6-AMINOISOQUINOLINES AND USES THEREOF | AADAT, SLC10A1, SLC10A2 | ROCK2 3307/4885ROCK1 3706/4885MYLK4 2031/4885 |
| US-20120135984-A1 | DUAL-ACTION INHBITORS AND METHODS OF USING SAME | SLC6A2, ROCK2, SLC6A4 | ROCK2 2/4885ROCK1 6/4885MYLK4 196/4885 |
| US-20100280011-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | ROCK2 3/4885ROCK1 10/4885MYLK4 146/4885 |
| US-12478577-B2 | Pharmaceutical compositions for treating ocular diseases or disorders | PDE6D, PDE6C, PDE6A | ROCK2 1763/4885ROCK1 1280/4885MYLK4 2494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.